Biocon’s subsidiary -- Biocon Pharma has secured approval from Health Canada for Micafungin for injection, USP, 50 mg and 100 mg. The approved product is indicated for use in adults and children four months and older for treatment of patients with Candidemia, Acute Disseminated Candidiasis, Candida Peritonitis and Abscesses infections; treatment of patients with esophageal candidiasis; and prophylaxis of Candida infections in patients undergoing hematopoietic stem cell transplantation. The approval will further strengthen the company’s integrated biosimilars and generics portfolio.
Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.
